Dr. Reddy’s Laboratories introduces Toripalimab in India for nasopharyngeal carcinoma
India has now become the third country to have access to this PD-1 inhibitor, following the US and China. The drug will be marketed under the brand name
Gilead Sciences has entered into an exclusive option and license agreement with German biotechnology company Tubulis to develop an antibody-drug conjugate (ADC) aimed at treating solid tumours.